Cannabidiol and Management of Endometriosis Pain
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04527003 |
|
Recruitment Status :
Recruiting
First Posted : August 26, 2020
Last Update Posted : December 30, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Endometriosis CBD Pelvic Pain | Drug: Cannabidiol (CBD) Extract Drug: Norethindrone Acetate Other: Placebo | Phase 3 |
The proposal is to conduct a randomized double-blind placebo-controlled pilot study to evaluate the effectiveness of cannabidiol on the management of endometriosis-related pain.
Subjects will be pre-screened from new and existing patients as well as from referral sites for the diagnosis of endometriosis. Potential subjects will be pre-screened for moderate to severe endometriosis associated pain (VAS > 3) greater than 6 months. Those meeting all inclusion and exclusion criteria that who are willing to participate will receive a detailed history and physical exam, appropriate bloodwork and undergo informed consented at the Screening Visit. Baseline survey data will be collected. During Screening, the patient's will be asked to complete their daily electronic diaries and screened for daily reporting adherence.
Randomized subjects will receive either (1) placebo (2) low dose CBD (3) high dose CBD. This study will include an 8-week intervention period during which subjects will be asked to record daily electronic VAS scores, pain medication use and a number of other parameters. Subjects will return at week 12 for a 4 week post-treatment visit, where they can also chose to enroll in an optional pharmacokinetic study. Participants will complete the Endometriosis Health Profile-30 (EHP-30), Patient Global Assessments (PGAs), the Patient Global Impression of Change (PGIC) surveys and, if partnered and sexually active, the Female Sexual Function Index at various time points. Patients will also have bloodwork done to assess for circulating markers of inflammation, circulating CBD concentration levels and liver dysfunction throughout the study duration. Subjects will be screened for side effects and asked to record pain medication use throughout the duration of the study. Study drug compliance will be assessed.
At the completion of the study, all subjects will be offered the opportunity to do pharmacokinetic testing with sublingual CBD until a maximum number of 4 patients are enrolled. The testing will include 24 hours of monitoring with sequential blood draws to determine the pharmacokinetic parameters of sublingual CBD after administration and one salivary pH. They will be discharged at 24 hours and asked to return to the clinic at 48 hours for one final lab draw.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 36 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Masking Description: | Double-blind of study team (PI, Sub-I's and all research staff) and subjects. Randomization will be completed by Investigational Pharmacy and will keep the blind. |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain |
| Actual Study Start Date : | December 4, 2020 |
| Estimated Primary Completion Date : | June 30, 2023 |
| Estimated Study Completion Date : | December 1, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Group A - Placebo
Norethindrone acetate (5mg daily) + Placebo
|
Drug: Norethindrone Acetate
Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation. Other: Placebo a substance or treatment which is designed to have no therapeutic value |
|
Active Comparator: Group B - Low Dose CBD
Norethindrone acetate (5mg daily) + Low dose CBD (10mg sublingual daily)
|
Drug: Cannabidiol (CBD) Extract
Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system. Drug: Norethindrone Acetate Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation. |
|
Active Comparator: Group C - High Dose CBD
Norethindrone acetate (5mg daily) + High dose CBD (20mg sublingual daily)
|
Drug: Cannabidiol (CBD) Extract
Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system. Drug: Norethindrone Acetate Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation. |
- Pain Score [ Time Frame: 8 weeks ]Pain will be reported daily using the Visual Analog Scale, a 100mm horizontal line on which the patient's pain intensity is represented by a point between the extremities of 0 (no pain) and 100 (worst pain). The primary study endpoint will be compared between groups using the area under the curve.
- Change in Total FSFI Score [ Time Frame: Baseline and 12 weeks ]The Female Sexual Function Index (FSFI) is a validated survey. The total FSFI score ranges from 2 (low sexual function) to 36 (high sexual function).
- Change in EHP-30 Core Domain [ Time Frame: Baseline and 12 weeks ]The Endometriosis Health Profile-30 (EHP-30) is a validated questionnaire measuring quality of life in women with endometriosis. A summary score is calculated for the core domain on a scale of 0 to 100 (0 indicates the best possible health status whereas 100 indicates the worst possible health status).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Females ages 18-45 years at the time of enrollment who have a surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis with associated moderate to severe endometriosis related pain |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Females ages 18-45 years at the time of enrollment
- A surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis with associated moderate to severe endometriosis related pain ( > 3 on a VAS)
- Is not expected to undergo gynecological surgery or other surgical procedure for treatment of endometriosis during the study period
- Agrees to use approved contraception during the entire study if not surgically sterile
- Patients using oral contraceptives, vaginal ring, injectable progesterone and/or GnRH agonists/antagonist for contraception and/or management of endometriosis, can be included if both they and their primary provider agree to stopping their medication and transitioning to Norethindrone acetate (NETA) as the primary treatment of endometriosis throughout the study period.
- Patients using Long-acting reversible contraceptives (LARCs) for contraception and/or management of endometriosis can be included if both they and their primary provider agree to initiate Norethindrone (NETA) as the primary treatment of endometriosis throughout the study period
Exclusion Criteria:
- Women that are pregnant, breastfeeding or trying to conceive
- Women with chronic daily opioid use and any chronic pain or frequently reoccurring pain condition, other than endometriosis, that is treated with opioids for > 14 days per month.
- Women that are currently using Cannabis based products or have used them within 30 days of enrollment
- Non-English speaking or inability to read and understand English
- Women with a BMI > 35 kg/m2
- Women with known liver disease, such as hepatitis, or with screening LFTS (AST/ALT) > 3 times above the upper limits of normal (ULN) in the past year
- Women with chronic alcohol use (defined as > 3 drinks per day, averaged over one week)
- Women with chronic use of drugs (defined as > 10 days/month) that cause somnolence/sedation such as benzodiazepines or Central Nervous System (CNS) depressants that are unwilling or unable to discontinue the medications for the washout period and the duration of the study
- Women who are currently taking Clobazam or Valproate and are unwilling/unable to discontinue the medication for the washout period and the duration of the study
- Women with suicidal ideation or uncontrolled depression within the past year
- Known history of or suspected breast cancer on screening physical exam
- History of or active deep venous thrombosis or pulmonary embolism
- History of or active arterial thromboembolic event (e.g. stroke, myocardial infarction)
- Multiple (> 3) risk factors for arterial vascular disease (e.g. uncontrolled hypertension, diabetes mellitus, hypercholesterolemia, obesity and smoking)
- Current use of a progestin-containing contraceptive implant
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04527003
| Contact: Kristin Riley, MD | 7175316446 | kriley1@pennstatehealth.psu.edu | |
| Contact: Barbara Scheetz | 717-531-4483 | bscheetz@pennstatehealth.psu.edu |
| United States, Pennsylvania | |
| Penn State Health Milton S. Hershey Medical Center | Recruiting |
| Hershey, Pennsylvania, United States, 17033 | |
| Contact: Heidi N Watts, BSN, RN 717-531-6272 hwatts@pennstatehealth.psu.edu | |
Publications:
| Responsible Party: | Kristin Riley, MD, Assistant Professor of Obstetrics and Gynecology, Milton S. Hershey Medical Center |
| ClinicalTrials.gov Identifier: | NCT04527003 |
| Other Study ID Numbers: |
STUDY00013752 |
| First Posted: | August 26, 2020 Key Record Dates |
| Last Update Posted: | December 30, 2022 |
| Last Verified: | December 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
endometriosis CBD pelvic pain |
|
Endometriosis Pelvic Pain Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Diseases Pain Neurologic Manifestations Cannabidiol Norethindrone |
Norethindrone Acetate Anticonvulsants Contraceptives, Oral, Hormonal Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Contraceptive Agents, Hormonal Contraceptives, Oral, Synthetic |